For research use only. Not for therapeutic Use.
Tilfrinib (compound 4f) is a potent and selective Brk/PTK6 inhibitor with an IC50 value of 3.15 nM for Brk. Tilfrinib shows good anti-proliferative activity and has potential of anti-tumour[1][2].
Tilfrinib (20 µM; 36 h) shows inhibition of PTK6, and decreases the ETV4 WT-induced expression of CXCL1 or CXCL8 in UM-UC-3 cells and expression of VEGFA or MMP9 in TANs[1].
Tilfrinib (compound 4f) shows good anti-proliferative activity against MCF7, HS-578/T and BT-549 cells with GI50 values of 0.99, 1.02 and 1.58 µM[2].
| Catalog Number | I009815 |
| CAS Number | 1600515-49-8 |
| Synonyms | 3-(9H-pyrido[2,3-b]indol-4-ylamino)phenol |
| Molecular Formula | C17H13N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C17H13N3O/c21-12-5-3-4-11(10-12)19-15-8-9-18-17-16(15)13-6-1-2-7-14(13)20-17/h1-10,21H,(H2,18,19,20) |
| InChIKey | RXPZOSHFGJWSLQ-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C3=C(C=CN=C3N2)NC4=CC(=CC=C4)O |
| Reference | [1]. Zhang Q, Liu S, et al. ETV4 mediated tumor-associated neutrophil recruitment promotes lymphangiogenesis and lymphatic metastasis of bladder cancer[J]. 2022. [2]. Mahmoud KA, et al. Discovery of 4-anilino α-carbolines as novel Brk inhibitors. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1948-51. |
